T1	Participants 246 262	cancer patients.
T2	Participants 473 529	patients undergoing therapy with neurotoxic chemotherapy
T3	Participants 768 788	100 patients per arm
T4	Participants 939 1071	Two-hundred seven patients were enrolled between December 1, 2006 and December 14, 2007, producing 189 evaluable cases for analysis.
T5	Participants 1702 1761	studied group of patients receiving neurotoxic chemotherapy
